<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435993</url>
  </required_header>
  <id_info>
    <org_study_id>114840</org_study_id>
    <nct_id>NCT01435993</nct_id>
  </id_info>
  <brief_title>Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis</brief_title>
  <official_title>A Randomized, Single Blind, Placebo-controlled, Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 in Patients With Relapsing Forms of Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate an experimental new drug, GSK1223249 in patients diagnosed with
      relapsing forms of multiple sclerosis. The study will specifically investigate safety (vital
      signs like heart rate, blood pressure, Magnetic Resonance Imaging (MRI), and other markers of
      health from blood samples), tolerability (any side effects that occur, if any), and
      pharmacokinetics (how the body processes the drug and how long the drug stays in the blood,
      and in cerebro-spinal fluid). The study will also investigate if patients' own immune system
      interacts with GSK1223249.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomised, placebo-controlled, single-blind (Investigator and Subject),
      single and repeat ascending dose protocol, in multiple sclerosis patients. The study is
      designed to evaluate the safety, tolerability, pharmacokinetics, and any potential for
      immunogenicity of GSK1223249 (a monoclonal antibody raised against Nogo-A), given
      intravenously in Multiple Sclerosis patients. The study will also evaluate exploratory
      endpoints including para-clinical activity via magnetic resonance imaging, cerebrospinal
      fluid pharmacokinetics, and effect of repeat dose administration of GSK1223249 on disability.
      Furthermore MS symptoms, such as relapses and individual symptom severity will be closely
      monitored.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">September 8, 2011</start_date>
  <completion_date type="Actual">January 23, 2012</completion_date>
  <primary_completion_date type="Actual">January 23, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>every 2-4 weeks over 7 months</time_frame>
    <description>• Changes in vital signs, ECG monitoring, blood chemistry, haematology, urinalysis, monitoring of AEs and MS relapses (number, incidence, severity)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax values and AUC(0-∞)</measure>
    <time_frame>Pre-dose; 1hr; 6hr; 12hr; 48hr; Day7; Day13; Follow-up</time_frame>
    <description>Profile of Pharamcokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of GSK1223249 in MS patients</measure>
    <time_frame>Predose; Day 85; Day169; Day197</time_frame>
    <description>• Presence of antibodies to GSK1223249 to be assessed in serum samples using validated ECL assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of GSK1223249 in cerebro-spinal fluid (CSF) in MS patients</measure>
    <time_frame>Day7; or Day 29; or Day 35; or Day 85</time_frame>
    <description>Measurement of GSK1223249 in CSF</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK1223249 slow (60 minutes) intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline slow (60 minutes) intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1223249</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>placebo intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with a relapsing form of MS .

          -  Using one of the following ongoing MS treatment strategies, defined as

               1. Currently receiving Beta-interferon/Copaxone for treatment of MS and have been
                  receiving the current course of therapy for 3 or more months prior to screening,
                  OR

               2. Not currently receiving disease modifying therapies for treatment of MS, and has
                  not received such therapies for at least 3 months prior to screening.

          -  Demonstrated clinical activity in 2 years prior to screening, whilst receiving
             current/previous treatment regimen or prior to any treatment regimen

          -  Expanded Disability Status Scale (EDSS) score ≤6.0 at either the screening or baseline
             visit.

          -  Male or female between 18 and 60 years of age inclusive, at the time of signing the
             informed consent.

          -  Body weight equal to or greater than: 50 kilogrammes

        Exclusion Criteria:

          -  Complications/History of other diseases that may impact on safety of patients enroling
             into the study.

          -  Liver function test outside normal range for patient population

          -  Treatment with methylprednisolone or any other systemic steroid, for a relapse or
             otherwise, within 30 days of screening

          -  Treatment in the past 6 months with any of the following agents: Fingolimod (Gilenya),
             methotrexate, mitoxantrone, azathioprine, or other small molecule immunosuppressants.

          -  History of anaphilaxis to protein based therapeutics or mono-clonal antibodies.

          -  Positive result for Hapatitis B, HIV, and/or drugs of abuse, or excessive alcohol
             consumption.

          -  Not able to undergo MRI scanning safely, or Gadolinium (contrast enhancing agents)
             during MRI.

          -  Other significant infections e.g. Tuberculosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/114840?search=study&amp;study_ids=114840#rs</url>
    <description>Results for study 114840 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis, Secondary-Progressive with relapses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114840</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114840</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114840</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114840</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114840</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114840</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114840</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

